6. Genmab A/S (NASDAQ:GMAB)
Genmab A/S is being viewed as a value opportunity following a recent pullback tied to a failed confirmatory study. On March 26, Wolfe Research initiated coverage with an Outperform rating and a $32 price target, citing upcoming clinical catalysts in 2026.
The firm identified Epkinly as a key driver, projecting $3.4 billion in peak sales. The frontline EPCORE DLBCL-2 study is expected to serve as the primary value inflection point.
Another pipeline asset, Rina-S, is projected to generate $2.5 billion in peak sales across multiple indications. Data from the RAINFOL-01 PROC study is expected later this year, providing another near-term catalyst.
On the commercial side, DARZALEX continues to deliver strong revenue. The drug generated $3.964 billion in global net sales in Q1 2026, with $2.208 billion coming from the U.S. and $1.756 billion from international markets.
Despite recent setbacks, the company’s diversified oncology portfolio and upcoming clinical readouts keep it positioned for recovery and growth.
YOU MUST READ THIS: Top 10 Microcap Biotech Stocks That Could Multiply Your Money Fast
Click here to continue reading and checkout the Top 5 Best Biotech Stocks Wall Street Is Buying Aggressively Now.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
